COMMUNIQUÉS West-GlobeNewswire

Olema Oncology to Participate in Upcoming Investor Conferences
19/05/2026
SAN FRANCISCO, May 19, 2026 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and [...]
RxSight, Inc. to Present at the Stifel 2026 Virtual Ophthalmology Forum
19/05/2026
ALISO VIEJO, Calif., May 19, 2026 (GLOBE NEWSWIRE) -- (NASDAQ: RXST) RxSight, Inc., today announced plans to participate in the upcoming Stifel 2026 Virtual Ophthalmology Forum. Management is scheduled to participate in [...]
Ipsen announces late-breaking data from first head-to-head study comparing Dysport® and Botox® in adults with upper limb spasticity
19/05/2026
Phase IV head-to-head, double-blind trial comparing safety and efficacy met its primary and secondary endpoints The DIRECTION trial results show the safety profile for Dysport ® (abobotulinumtoxinA) was non-inferior to [...]
Monopar Announces Publication of Phase 2 Study Demonstrating ALXN1840 Significantly Improves Copper Balance in Patients with Wilson Disease
19/05/2026
WILMETTE, Ill., May 19, 2026 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (“Monopar” or the “Company”) (Nasdaq: MNPR), a clinical-stage biopharmaceutical company developing innovative treatments for patients with unmet [...]
Resmed Announces Participation in the 46th Annual William Blair Growth Stock Conference
19/05/2026
SAN DIEGO, May 19, 2026 (GLOBE NEWSWIRE) -- Resmed (NYSE: RMD, ASX: RMD) today announced Mick Farrell, chairman and chief executive officer, and Aaron Bloomer, chief financial officer, will attend the 46 th Annual [...]
Eton Pharmaceuticals Expands Rare Disease Portfolio Through Agreement for U.S. Commercialization Rights to IMPAVIDO® (miltefosine)
19/05/2026
IMPAVIDO ® is the first and only FDA-approved oral therapy for visceral, cutaneous, and mucosal leishmaniasis caused by specific Leishmania species Leishmaniasis is a rare but potentially life-threatening parasitic [...]
Vaxart Files Preliminary Proxy Statement and Issues Open Letter to Shareholders
19/05/2026
Company is Entering a Pivotal Phase to Demonstrate Value of its Unique Oral Vaccine Platform Emphasizes Need for the Right Board Leadership at Critical Strategic Juncture Encourages Shareholders to Visit Vote.Vaxart.com [...]
Alps Group Inc Announces Receipt of Nasdaq Notification Regarding Minimum Bid Price Deficiency
19/05/2026
KUALA LUMPUR, Malaysia, May 19, 2026 (GLOBE NEWSWIRE) -- Alps Group Inc (the “Company” or “Alps Group”), the parent company of Alps Life Sciences Inc. (“Alps Holdco”), a fully integrated biotechnology research and [...]
Journey Medical Corporation to Participate in A.G.P.’s Annual Virtual Healthcare Conference
19/05/2026
SCOTTSDALE, Ariz., May 19, 2026 (GLOBE NEWSWIRE) -- Journey Medical Corporation (Nasdaq: DERM) (“Journey Medical,” “the Company,” “we” or “our”), a commercial-stage pharmaceutical company focused on developing, selling [...]
Artiva Biotherapeutics Announces Multiple AlloNK® Data Presentations at EULAR 2026 Congress, Including Late-Breaking Oral Presentation Highlighting Clinical Efficacy Comparable to Autologous CAR T-Cell Therapy in Rheumatologic Diseases
19/05/2026
Late-breaking oral presentation to highlight AlloNK + rituximab clinical responses comparable to autologous CAR T-cell therapy in 31 patients with rheumatologic diseases, including 71% ACR50 response in refractory [...]
Annovis Announces Launch of Proposed Public Offering of Common Stock and Accompanying Warrants
19/05/2026
MALVERN, Pa., May 19, 2026 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a Phase 3 clinical-stage biotechnology company developing the investigational oral therapy, buntanetap, for [...]
Ozari Health Launches Nationwide Telehealth Platform for Compounded Semaglutide and Tirzepatide Starting at $86 Per Month
19/05/2026
LegitScript-verified platform connects patients with licensed providers for GLP-1 weight loss treatment, with transparent pricing, multiple pharmacy options, and no long-term contracts. New York, NY, May 19, 2026 (GLOBE [...]
Cadrenal Therapeutics to Participate in the Lytham Partners Spring 2026 Investor Conference on May 28, 2026
19/05/2026
PONTE VEDRA, Fla., May 19, 2026 (GLOBE NEWSWIRE) -- Cadrenal Therapeutics, Inc. (Nasdaq: CVKD), a late-stage biopharmaceutical company advancing novel therapies for life-threatening immune and thrombotic conditions, [...]
Iridex Reports First Quarter 2026 Financial Results
19/05/2026
2026 Guidance Affirmed MOUNTAIN VIEW, Calif., May 19, 2026 (GLOBE NEWSWIRE) -- Iridex Corporation (Nasdaq: IRIX), a worldwide leader providing innovative and versatile laser-based medical systems, delivery devices, and [...]
Suja Life to Report First Quarter 2026 Financial Results on June 9, 2026
19/05/2026
OCEANSIDE, Calif., May 19, 2026 (GLOBE NEWSWIRE) -- Suja Life, Inc. (NASDAQ: SUJA) (“Suja Life” or the “Company”), a leading better-for-you beverage company and maker of Suja Organic , Vive Organic , and Slice Soda , [...]
Oorja Bio Unveils Clinical Data for ORJ-001, a First-in-Class Therapeutic Targeting Alveolar Epithelial Type 2 (AEC2) Cells for Treatment of Idiopathic Pulmonary Fibrosis (IPF)
19/05/2026
ORJ-001 achieved therapeutic exposure and was well tolerated in Phase 1 study, supporting company’s plans to initiate Phase 2 clinical trial in IPF patients Data from preclinical studies of ORJ-001 demonstrated durable [...]
Oorja Bio Launches as a Clinical-Stage Company to Develop Groundbreaking Therapies for Idiopathic Pulmonary Fibrosis (IPF) and Other Fibrotic Diseases
19/05/2026
Company announces $30 million Series A financing and founding leadership team with expertise in pulmonary drug innovation and track record advancing novel therapies to patients ORJ-001, set to begin a Phase 2 clinical [...]
Comfort Keepers Ireland Highlights Urgent Need for Dementia Care as Cases Set to Double by 2045
19/05/2026
Report Reveals 64,000 People Currently Living with Dementia in Ireland, Emphasizing Home-Based Support Dublin, IRELAND, May 19, 2026 (GLOBE NEWSWIRE) -- A new industry report from Comfort Keepers Ireland has underscored [...]
Achieve Life Sciences Presents Safety Data from 52 Weeks of Continuous Cytisinicline Treatment
19/05/2026
ORCA-OL data complete the clinical evidence package supporting the cytisinicline smoking cessation NDA No new safety signals identified by the independent Data Safety Monitoring Committee over 52 weeks of continuous [...]

Pages